TEM vs VEEV Stock Comparison: AI Score, Valuation, Performance and Upside
Tempus AI is an earlier-stage, faster-growing precision medicine data company building a genomics and AI-driven dataset that is not yet consistently profitable, while Veeva Systems is a mature, highly profitable life sciences software leader with an entrenched CRM and content management franchise. The better stock depends on whether an investor prefers Tempus's higher-growth, data-driven healthcare AI thesis or Veeva's proven, cash-generative SaaS model.
Use this TEM vs VEEV comparison to weigh earlier-stage healthcare AI data growth against mature, profitable life sciences software compounding. Tempus offers more speculative upside tied to its genomic data moat and pharma partnerships; Veeva offers durable, already-profitable exposure to life sciences digital operations.
VEEV holds the edge across 4 of 5 key metrics in this comparison. TEM has delivered stronger 1-year price return (-5.24% vs -12.18%), though VEEV has the better forward P/E setup (24.72x vs -4782.24x for TEM). On fundamentals, TEM is growing revenue faster (21.60%), while VEEV maintains the higher operating margin (30.93%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for VEEV (+2.29%) than for TEM (-12.84%).
- Believe Tempus's proprietary genomic and clinical dataset can become a durable competitive moat
- Want exposure to the intersection of AI, genomics, and precision medicine as a long-term secular theme
- Are comfortable with pre-consistent-profitability risk in exchange for higher growth potential
- Value diversified revenue from both diagnostics and pharma data licensing
- Want an already-profitable, high-margin SaaS leader with an entrenched life sciences customer base
- Prefer lower business-model risk than an earlier-stage healthcare AI/data company
- Value strong free cash flow generation and a long track record of product expansion
- Are comfortable with more moderate growth as the core CRM market matures
| Metric | TEM | VEEV |
|---|---|---|
| AI score | 30.0 | 53.4 |
| AI rank | #2273 | #296 |
| Latest close | $72.69 | $247.90 |
| 1M return | +54.79% | +34.33% |
| 6M return | +21.23% | +35.78% |
| 1Y return | -5.24% | -12.18% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | TEM | VEEV |
|---|---|---|
| 1Y ago | $9.48K (-5.2%) started 2025-08-21 | $8.78K (-12.2%) started 2025-08-21 |
| 5Y ago | $18.06K (+80.6%) started 2024-06-14 | $7.69K (-23.1%) started 2021-08-23 |
| 10Y ago | $18.06K (+80.6%) started 2024-06-14 | $62.92K (+529.2%) started 2016-08-22 |
Hypothetical — past performance does not guarantee future results.
| Metric | TEM | VEEV |
|---|---|---|
| Market cap | $13.12B | $40.27B |
| Trailing P/E | N/A | 43.88 |
| Forward P/E | -4782.24 | 24.72 |
| Price/Sales | 9.16 | 12.13 |
| EV/Revenue | 9.60 | 9.96 |
| Analyst target | $63.36 | $253.57 |
| Target upside | -12.84% | +2.29% |
| Metric | TEM | VEEV |
|---|---|---|
| Revenue growth | 21.60% | 16.30% |
| Earnings growth | N/A | 14.60% |
| EPS growth | N/A | +14.60% |
| FCF margin | -6.53% | +37.95% |
| Operating margin | -20.11% | 30.93% |
| Profit margin | -17.77% | 28.37% |
| ROIC proxy | -67.44% | 13.93% |
| Return on equity | -67.44% | 13.93% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 3.58 | 0.92 |
| Debt/equity | 324.58 | 1.41 |
| Current ratio | 3.30 | 4.74 |
| Quick ratio | 3.01 | 4.67 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | TEM | VEEV |
|---|---|---|---|
| 1Y | Growth | -5.24% | -12.18% |
| CAGR | -5.24% | -12.19% | |
| Sharpe ratio | 0.21 | -0.23 | |
| Max drawdown | 59.76% | 50.55% | |
| Max daily drop | 12.36% | 9.77% | |
| Max wkly drop | 20.36% | 16.81% | |
| 5Y | Growth | +80.60% | -23.12% |
| CAGR | +31.07% | -5.13% | |
| Sharpe ratio | 0.71 | -0.06 | |
| Max drawdown | 59.76% | 54.74% | |
| Max daily drop | 19.23% | 16.24% | |
| Max wkly drop | 37.12% | 21.64% | |
| 10Y | Growth | +80.60% | +529.19% |
| CAGR | +31.07% | +20.20% | |
| Sharpe ratio | 0.71 | 0.55 | |
| Max drawdown | 59.76% | 55.69% | |
| Max daily drop | 19.23% | 16.24% | |
| Max wkly drop | 37.12% | 21.64% |
| Category | TEM | VEEV |
|---|---|---|
| Company | Tempus AI, Inc. | Veeva Systems Inc. |
| Sector | Healthcare Technology | Healthcare Technology |
| Industry | N/A | N/A |
| Core business | Precision medicine company combining genomic sequencing, clinical data, and AI-driven analytics to help physicians and pharmaceutical companies make data-informed treatment and drug-development decisions, monetizing through diagnostic testing and data-licensing partnerships. | Provider of cloud-based software for the life sciences industry, including customer relationship management (Veeva CRM) and content/quality management (Veeva Vault), used by pharmaceutical and biotech companies to manage regulatory, clinical, and commercial operations. |
| Investor focus | Revenue growth across diagnostics and data-licensing segments, path to profitability, expansion of pharma data partnerships, and growth of its proprietary genomic and clinical database. | Subscription revenue growth, customer retention and expansion within the life sciences vertical, profitability and free cash flow margins, and progress of newer product lines beyond core CRM. |
- Large and growing proprietary dataset combining genomic, clinical, and outcomes data creates a potential data moat
- Dual revenue streams from diagnostic testing and data licensing to pharmaceutical partners diversify the business model
- Positioned at the intersection of AI, genomics, and precision medicine — a high-growth secular healthcare theme
- Dominant, entrenched position in life sciences CRM and content management software with high switching costs
- Consistently profitable, high-margin SaaS business model with strong free cash flow generation
- Long track record of successful product expansion (Vault, Compass data, clinical products) within its core vertical
- Continued path to sustained profitability amid high research, sales, and data infrastructure investment
- Reimbursement and regulatory risk associated with diagnostic testing revenue
- Competitive risk from other genomics and precision medicine data companies pursuing similar pharma partnerships
- Growth deceleration risk as its core life sciences CRM market matures and penetration increases
- Customer concentration within the pharmaceutical and biotech industry ties growth to that sector's spending cycles
- Competitive risk from broader enterprise CRM and data platforms attempting to enter life sciences
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.